Posts tagged “Biotech & Life Science”
Siemens, GSK joint venture team for personalized diagnostic drug tests
An HIV/AIDS treatment developed by GlaxoSmithKline is now being studied with Siemens to develop companion diagnostics that doctors can use to select patients appropriate for the treatment.
Co-founder of CoLucid Pharmaceuticals in Durham dies
Dr. James White, a long-time pharmaceutical executive, launched CoLucid in 2005 along with Art Pappas of Pappas Ventures in Durham.
Tale of two drug giants: GSK's pipeline full, AstraZeneca's dwindles
Analysis: While AstraZeneca cuts, GSK is putting itself in a position to discover, develop and position for approval of a wider array of potential drug candidates. It's a strategy that should pay off in the best of times, and the worst of times.
Drug research
GSK is back in the black but reason to cheer?
Chief Executive Officer Andrew Witty used the quarterly performance to tout his performance as CEO and multiple advances in the drug giant's product pipeline. However, two analysts are cautious about the news.
GSK Headquarters
Salix drug receives priority FDA review, but partner wants it back
The Raleigh firm is tied up in a law suit over the development of the drug that's intended to help AIDS patients suffering with diarrhea.
GSK state of the company 2012: From headwinds to tailwinds, says CEO
Andrew Witty, in his fourth year as chief executive officer at GlaxoSmithKline, provides a state of the company overview as GSK reports a return to profitability in the fourth quarter. "For us the headwinds that we've faced for the last four or five years are diminishing, and we've been building more of our own tailwinds in terms of our R&D portfolio and the investment we've been making in our new growth business like emerging markets, consumer, the vaccine business," he says. Witty is also especially excited about progress in R&D.
Andrew Witty
ChannelAdvisor ecommerce webinar; Precision BioSciences patents; Sales Performance to China; Argos drug update
Local tech briefs: ChannelAdvisor to host ecommerce webinar; Precision secures two more patents; Charlotte-based SPI expands to China; Argos touts drug progress.
Startup Chimerix reports positive test news for transplant drug
The company is studying the compound for the prevention of cytomegalovirus diseases, or CMV, in patients who have had stem cell transplants.
GSK puts four clinical trials on hold, development partner says
Anacor Pharmaceuticals discloses that GlaxoSmithKline "voluntarily passed" enrollment in the trials due to a "recently identified microbiological finding" in some patients.
Raleigh-based BioDelivery Sciences gears to raise $40M
The Raleigh-based specialty pharmaceutical company has filed a shelf registration that would allow BDSI to raise up to $40 million by selling stock if it needs the money.
UNC Nutrition Research Institute lands $1M endowment
The gift will create the NRI's first endowed distinguished professorship, The Dickson Foundation-Harris Teeter Distinguished Professorship in Nutrition. Once fully endowed, this professorship will generate an annual disbursement to support a designated Nutrition Research Institute faculty member and foster scientific discovery.
Lower IPO forces changes in CH-based Cempra drug trial plans
When Cempra initially filed to go public last October, the company said proceeds from the offering would finance four phase 3 clinical trials. But with the smaller stock offering, Cempra needs to scale back those plans.
Cemrpa's product lineup, progress
Big pharma could help FDA improve communications
Opinion: The Food and Drug Administration doesn't achieve the impact it's looking for in communications with physicians. The private sector could help.
Life science news in review: MedCity News headlines
A look back at headlines from MedCity news for the week of Jan. 30-Feb. 5:
E-mail Preferences
MedCity
- Market for flu test kit expanded to Japan
- Stem cell therapeutics firm Aldagen acquired by Cytomedix in stock deal
- Focus on health and wellness leads a Minnesota health system to change name
- Success or withdrawal hang in balance for Shire blood pressure drug
- MN employers embrace private health insurance exchange to manage costs